{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:46:41Z","timestamp":1769071601187,"version":"3.49.0"},"publisher-location":"Cham","reference-count":57,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032174185","type":"print"},{"value":"9783032174192","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/5584_2025_873","type":"book-chapter","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:41:29Z","timestamp":1751028089000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant Cyclophosphamide"],"prefix":"10.1007","author":[{"given":"Taner","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehra Narl\u0131","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem Civriz","family":"Bozda\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"10","key":"873_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R et al (2016) Severe cytokine-release syndrome after T cell\u2013replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti\u2013IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant 22(10):1851\u20131860","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"873_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","volume":"21","author":"AS Al-Homsi","year":"2015","unstructured":"Al-Homsi AS et al (2015) Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 21(4):604\u2013611","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"873_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hemonc.2017.03.001","volume":"10","author":"M Arango","year":"2017","unstructured":"Arango M, Combariza JF (2017) Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. Hematol Oncol Stem Cell Ther 10(2):79\u201384","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"873_CR4","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1038\/bmt.2015.93","volume":"50","author":"A Bacigalupo","year":"2015","unstructured":"Bacigalupo A et al (2015) Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant 50(2):S37\u2013S39","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"873_CR5","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","volume":"35","author":"A Bashey","year":"2017","unstructured":"Bashey A et al (2017) Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol 35(26):3002\u20133009","journal-title":"J Clin Oncol"},{"issue":"25","key":"873_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J et al (2023) Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med 388(25):2338\u20132348","journal-title":"N Engl J Med"},{"issue":"12","key":"873_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.7326\/0003-4819-129-12-199812150-00007","volume":"129","author":"RA Brodsky","year":"1998","unstructured":"Brodsky RA et al (1998) Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 129(12):1031\u20131035","journal-title":"Ann Intern Med"},{"issue":"5","key":"873_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","volume":"20","author":"L Castagna","year":"2014","unstructured":"Castagna L et al (2014) Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 20(5):724\u2013729","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"873_CR9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","volume":"21","author":"N Cieri","year":"2015","unstructured":"Cieri N et al (2015) Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant 21(8):1506\u20131514","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"873_CR10","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C et al (2014) Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124(8):1372\u20131377","journal-title":"Blood"},{"issue":"8","key":"873_CR11","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A et al (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26(8):e177\u2013e182","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"873_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","volume":"55","author":"R El Fakih","year":"2020","unstructured":"El Fakih R et al (2020) Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant 55(1):40\u201347","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"873_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","volume":"124","author":"S Ganguly","year":"2014","unstructured":"Ganguly S et al (2014) Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood 124(13):2131\u20132141","journal-title":"Blood"},{"issue":"11","key":"873_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.bbmt.2019.06.029","volume":"25","author":"M Gooptu","year":"2019","unstructured":"Gooptu M et al (2019) Effect of sirolimus on immune reconstitution following Myeloablative allogeneic stem cell transplantation: an ancillary analysis of a randomized controlled trial comparing tacrolimus\/sirolimus and tacrolimus\/methotrexate (blood and marrow transplant clinical trials network\/BMT CTN 0402). Biol Blood Marrow Transplant 25(11):2143\u20132151","journal-title":"Biol Blood Marrow Transplant"},{"key":"873_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101053","volume":"62","author":"M Gooptu","year":"2023","unstructured":"Gooptu M, Bolanos-Meade J, Koreth J (2023) Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond. Blood Rev 62:101053","journal-title":"Blood Rev"},{"issue":"10","key":"873_CR16","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.bbmt.2018.05.024","volume":"24","author":"E Huselton","year":"2018","unstructured":"Huselton E et al (2018) Propensity score analysis of conditioning intensity in peripheral blood haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(10):2047\u20132055","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"873_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M et al (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119(1):296\u2013307","journal-title":"Blood"},{"issue":"14","key":"873_CR18","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/cancers16142567","volume":"16","author":"A Ju\u00e1rez","year":"2024","unstructured":"Ju\u00e1rez A et al (2024) Reduced dose of post-transplant cyclophosphamide with tacrolimus for the prevention of graft-versus-host disease in HLA-matched donor peripheral blood stem cell transplants: a prospective pilot study. Cancers 16(14):2567","journal-title":"Cancers"},{"issue":"211","key":"873_CR19","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","volume":"5","author":"CG Kanakry","year":"2013","unstructured":"Kanakry CG et al (2013) Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 5(211):211ra157","journal-title":"Sci Transl Med"},{"key":"873_CR20","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.3389\/fimmu.2019.03138","volume":"10","author":"K Kato","year":"2020","unstructured":"Kato K et al (2020) Cyclophosphamide-induced tolerance in allogeneic transplantation: from basic studies to clinical application. Front Immunol 10:3138","journal-title":"Front Immunol"},{"issue":"2","key":"873_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195","journal-title":"Blood"},{"issue":"11","key":"873_CR22","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","volume":"102","author":"CJ Lee","year":"2017","unstructured":"Lee CJ et al (2017) Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Haematologica 102(11):1810\u20131822","journal-title":"Haematologica"},{"issue":"10","key":"873_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/cncr.30534","volume":"123","author":"CJ Lin","year":"2017","unstructured":"Lin CJ et al (2017) Cardiomyopathy in patients after posttransplant cyclophosphamide\u2013based hematopoietic cell transplantation. Cancer 123(10):1800\u20131809","journal-title":"Cancer"},{"issue":"6","key":"873_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641\u2013650","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"873_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O'Donnell PV, Fuchs EJ (2012) Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 39(6):683\u2013693","journal-title":"Semin Oncol"},{"issue":"4","key":"873_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik L et al (2022) Randomized phase III BMT CTN trial of Calcineurin inhibitor-free chronic graft-versus-host disease interventions in Myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol 40(4):356\u2013368","journal-title":"J Clin Oncol"},{"issue":"3","key":"873_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4049\/jimmunol.150.3.753","volume":"150","author":"T Maeda","year":"1993","unstructured":"Maeda T et al (1993) Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. J Immunol 150(3):753\u2013762","journal-title":"J Immunol"},{"issue":"5","key":"873_CR28","doi-asserted-by":"publisher","first-page":"313 e1","DOI":"10.1016\/j.jtct.2023.01.009","volume":"29","author":"J Marco-Ayala","year":"2023","unstructured":"Marco-Ayala J et al (2023) Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation. Transplant Cell Ther 29(5):313 e1\u2013313 e10","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"873_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","volume":"195","author":"H Mayumi","year":"1996","unstructured":"Mayumi H, Umesue M, Nomoto K (1996) Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 195(2):129\u2013139","journal-title":"Immunobiology"},{"key":"873_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101093","volume":"62","author":"SR McCurdy","year":"2023","unstructured":"McCurdy SR, Luznik L (2023) Relapse after allogeneic transplantation with post-transplant cyclophosphamide: shattering myths and evolving insight. Blood Rev 62:101093","journal-title":"Blood Rev"},{"issue":"19","key":"873_CR31","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR et al (2015) Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125(19):3024\u20133031","journal-title":"Blood"},{"issue":"2","key":"873_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3324\/haematol.2016.144139","volume":"102","author":"SR McCurdy","year":"2017","unstructured":"McCurdy SR et al (2017) Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 102(2):391","journal-title":"Haematologica"},{"issue":"2","key":"873_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2017.10.023","volume":"24","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR et al (2018a) Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide. Biol Blood Marrow Transplant 24(2):343\u2013352","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"873_CR34","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.bbmt.2018.06.004","volume":"24","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR et al (2018b) Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transplant 24(10):2056\u20132064","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"873_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jtct.2024.05.009","volume":"30","author":"LM Morsink","year":"2024","unstructured":"Morsink LM et al (2024) Improved outcome of allogeneic transplantation in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide and reduced duration of immune suppression. Transplant Cell Ther 30(8):794\u2013807","journal-title":"Transplant Cell Ther"},{"key":"873_CR36","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG (2019) Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol 10:2668","journal-title":"Front Immunol"},{"key":"873_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101034","volume":"62","author":"PV O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PV, Jones RJ (2023) The development of post-transplant cyclophosphamide: half a century of translational team science. Blood Rev 62:101034","journal-title":"Blood Rev"},{"issue":"7","key":"873_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","volume":"8","author":"PV O\u2019Donnell","year":"2002","unstructured":"O\u2019Donnell PV et al (2002a) Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8(7):377\u2013386","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"873_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","volume":"8","author":"P O\u2019Donnell","year":"2002","unstructured":"O\u2019Donnell P et al (2002b) Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8(7):377\u2013386","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"873_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2014.10.008","volume":"21","author":"P O\u2019Donnell","year":"2015","unstructured":"O\u2019Donnell P, Raj K, Pagliuca A (2015) High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 21(1):197\u2013198","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"873_CR41","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR et al (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 56(7):1651\u20131664","journal-title":"Bone Marrow Transplant"},{"key":"873_CR42","unstructured":"Pierini A, Williams L, Cirrone F, Cole K, Abdul-Hay M, Luznik L, Al-Homsi AS et al (2020) The immunobiology of HLA-haploidentical hematopoietic cell transplantation"},{"issue":"2","key":"873_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","volume":"102","author":"A Ruggeri","year":"2017","unstructured":"Ruggeri A et al (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica 102(2):401","journal-title":"Haematologica"},{"issue":"13","key":"873_CR44","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1080\/10428194.2020.1797010","volume":"61","author":"MQ Salas","year":"2020","unstructured":"Salas MQ et al (2020) High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma 61(13):3198\u20133208","journal-title":"Leuk Lymphoma"},{"issue":"28","key":"873_CR45","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC et al (2024) Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol 42(28):3277\u20133286","journal-title":"J Clin Oncol"},{"issue":"6","key":"873_CR46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcyt.2024.02.010","volume":"26","author":"S Shibata","year":"2024","unstructured":"Shibata S et al (2024) Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy 26(6):592\u2013598","journal-title":"Cytotherapy"},{"key":"873_CR47","doi-asserted-by":"crossref","unstructured":"Shimoni A et al (2024) Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia","DOI":"10.21203\/rs.3.rs-3972301\/v1"},{"issue":"10","key":"873_CR48","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1182\/blood-2017-01-761627","volume":"129","author":"A Spyridonidis","year":"2017","unstructured":"Spyridonidis A (2017) How much immunosuppression do we need? Blood 129(10):1241\u20131243","journal-title":"Blood"},{"issue":"12","key":"873_CR49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729\u2013735","journal-title":"N Engl J Med"},{"issue":"4","key":"873_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2141.1989.tb04325.x","volume":"72","author":"R Storb","year":"1989","unstructured":"Storb R et al (1989) Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 72(4):567\u2013572","journal-title":"Br J Haematol"},{"issue":"2","key":"873_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","volume":"128","author":"G Strauss","year":"2002","unstructured":"Strauss G, Osen W, Debatin K-M (2002) Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128(2):255\u2013266","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"873_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12185-019-02660-8","volume":"110","author":"J Sugita","year":"2019","unstructured":"Sugita J (2019) HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol 110(1):30\u201338","journal-title":"Int J Hematol"},{"key":"873_CR53","doi-asserted-by":"crossref","unstructured":"Ulas T et al (2024) What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation? Transfus Apher Sci:104058","DOI":"10.1016\/j.transci.2024.104058"},{"issue":"6","key":"873_CR54","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP et al (2019) Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 129(6):2357\u20132373","journal-title":"J Clin Invest"},{"key":"873_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0781-y","volume":"12","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol 12:1\u20139","journal-title":"J Hematol Oncol"},{"issue":"26","key":"873_CR56","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579","journal-title":"N Engl J Med"},{"key":"873_CR57","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood-2023-189430","volume":"142","author":"H Zhang","year":"2023","unstructured":"Zhang H et al (2023) Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-identical peripheral blood hematopoietic stem cell transplantation. Blood 142:650","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Cell Biology and Translational Medicine, Volume 28"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2025_873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:02:29Z","timestamp":1769014949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2025_873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032174185","9783032174192"],"references-count":57,"URL":"https:\/\/doi.org\/10.1007\/5584_2025_873","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"28 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}